Replies to post #4604 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV 2Q25 Mavyret sales=$375M, +23% QoQ, +2% YoY:

https://investors.abbvie.com/static-files/a3a87cb9-4571-48a0-aa85-d355ae65a371

The FDA approved Mavyret for acute HCV on 6/11/25, so 2Q25 included only 2.5 weeks of the expanded label. Hence, the knock-on effects of the expanded label described in #msg-176309105 have not fully kicked in yet.